Clinical Trials
69 trialsNeoPACT
University of Kansas Medical Center
A Study of RC48-ADC for the Treatment of Locally Advanced or Metastatic Breast Cancer With Low Expression of HER2
RemeGen Co., Ltd.
CLOVER
Fudan University
Utidelone in Combination With AC Versus Docetaxel in Combination With AC for Neoadjuvant Chemotherapy in Patients With HER2-negative Breast Cancer
Beijing Biostar Pharmaceuticals Co., Ltd.
Study of KN026 Monotherapy or Combination Therapy in Patients With Metastatic Breast Cancer
Jiangsu Alphamab Biopharmaceuticals Co., Ltd
HIST-RIC
Institut Paoli-Calmettes
Evaluating Xihuang Pill to Improve the Efficacy of Neoadjuvant Chemotherapy for Breast Cancer
Zhejiang Provincial People's Hospital
easy laugh
Shanghai Pudong Hospital
A Study of Pyrotinib in Combination With Trastuzumab and Docetaxel in Patients With HER2 Metastatic Breast Cancer
Jiangsu HengRui Medicine Co., Ltd.
A Study of Immunotherapy Combined With Neoadjuvant Therapy Versus Neoadjuvant Therapy for Breast Cancer
Shengjing Hospital
Study of KN026 in Combination With Docetaxel as Neoadjuvant Therapy in HER2-positive Breast Cancer
Jiangsu Alphamab Biopharmaceuticals Co., Ltd
Clinical Study of Chidamide Combined With Chemotherapy in Neoadjuvant Treatment of HR+/ HER2-BC
Shengjing Hospital
Docetaxel and Cyclophosphamide Compared to Anthracycline-Based Chemotherapy in Treating Women With HER2-Negative Breast Cancer
NSABP Foundation Inc
Nab-paclitaxel Compared With Docetaxel in the Neoadjuvant Chemotherapy Breast Cancer
Zhejiang Provincial People's Hospital
Chidamide Combined With Exemestane (+/- Goserelin) Versus Neoadjuvant Chemotherapy in Patients of Stage II-III HR-positive/HER2-negative Breast Cancer
Shengjing Hospital
Pyrotinib as Neoadjuvant Agent for Non-objective Response HER2-positive Early Breast Cancer
The First Affiliated Hospital with Nanjing Medical University
Neoadjuvant Study of Navelbine in Patients With HER2 Positive Breast Cancer
Zhejiang Cancer Hospital
IMMUN-HER
Gruppo Oncologico Italiano di Ricerca Clinica
CAMELLIA
ChineseAMS
SOBER
Ruijin Hospital
Neoadjuvant Study of Pyrotinib in Patients With HER2 Positive Breast Cancer
Zhejiang Cancer Hospital
TENDENCY
Hebei Medical University Fourth Hospital
Cardiac Safety and Efficacy for Early-stage Breast Cancer Patients Treated With Pegylated Liposomal Doxorubicin(PLD)
Fudan University
ESNDBCP
Zhejiang University
Pyrotinib Combined With Docetaxel in the First-line Treatment of HER2-positive MBC
Zhejiang Cancer Hospital
TNT
Institute of Cancer Research, United Kingdom
NeoChAI
National Cancer Center, Korea
ACCN
Zhejiang Cancer Hospital
Marched Pair Study Conventional Doxorubicin(DOX) Versus Pegylated Liposomal Doxorubicin(PLD) Neoadjuvant Chemotherapy
Jilin University
Risk and Clinical Benefit of Chemotherapy and Intensive Endocrine Therapy for Luminal B1 Early-stage Breast Cancer
Shandong Cancer Hospital and Institute
Mutation Scores and Differential Protein Evaluating Efficacy in Adjuvant Chemotherapy in HER2(-) Luminal B Breast Cancer
Tianjin Medical University Cancer Institute and Hospital
Pathological Complete Response Rate in Locally Advanced Breast Cancer With FEC, EC-T, or TC as Neoadjuvant Chemotherapy
Shandong Cancer Hospital and Institute
Chemotherapy With or Without Bevacizumab in Treating Women With Stage I, Stage II, or Stage IIIA Breast Cancer That Can Be Removed By Surgery
NSABP Foundation Inc
NNBC3-Europe
Martin-Luther-Universität Halle-Wittenberg
Docetaxel 2-weeks Regimen in the Treatment of HER2 Negative Metastatic Breast Cancer
Zhejiang Cancer Hospital
Comparative Study on Two Post-operative Adjuvant Chemotherapy Regimens for Treating Triple-negative Breast Cancer
China Breast Cancer Clinical Study Group
TNM
Cancer Research Group - Collaborative Group, Beirut, Lebanon.
PERS
Sun Yat-sen University
PROMIX
Karolinska University Hospital
Docetaxel With or Without Low-dose, Short Course Sunitinib in Refractory Solid Tumors
National University Hospital, Singapore
Neoadjuvant Chemotherapy for Operable Premenopausal Breast Cancer Patients
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Neoadjuvant Chemotherapy With or Without Huaier Granule in Treating Women With Locally Advanced Breast Cancer That Can Be Removed By Surgery
Shandong University
A Study on Neoadjuvant Therapy for Her-2 Positive Breast Cancer and the Prognosis by Detecting CTCs
Hospital Affiliated to Military Medical Science, Beijing
Nimotuzumab Plus Docetaxel and Capecitabine Versus Docetaxel and Capecitabine in the Treatment of Breast Cancer Patients
ChineseAMS
Docetaxel Combined With Estramustine in Treating Women With Metastatic Breast Cancer
National Cancer Institute (NCI)
Chemotherapy Plus Peripheral Stem Cell Transplantation Compared With Chemotherapy Alone in Treating Women With Stage IV Breast Cancer
National Cancer Institute (NCI)
Epirubicin and Tamoxifen With or Without Docetaxel in Treating Postmenopausal Women With Breast Cancer
National Cancer Institute (NCI)
Validate Gene Expression and Proteomic Signatures Predictive of Treatment for Response for Breast Cancer Patient
National University Hospital, Singapore
Combination Chemotherapy in Treating Women With Breast Cancer
National Cancer Institute (NCI)
Docetaxel and Ifosfamide in Treating Women With Metastatic Breast Cancer
National Cancer Institute (NCI)